Alterity Therapeutics CEO to Provide Insights at Biotech Showcase

Author: Logan Wright Updated: 09-02-2025 07:29 AM

Alterity Therapeutics' Participation in Biotech Showcase

Alterity Therapeutics (NASDAQ: ATHE), a pioneering biotechnology company devoted to developing innovative disease-modifying treatments for neurodegenerative diseases, is thrilled to announce that David Stamler, M.D., the Company's Chief Executive Officer, will be delivering a corporate update at the upcoming Biotech Showcase. This noteworthy event is proudly hosted by Peak Asset Management and Monsoon Communications, promising a dynamic congregation of biotech innovators and investors.

Details of the Presentation

The presentation is scheduled for Wednesday, September 3, 2025, in Australia and will be simultaneously accessible for participants in the United States on Tuesday, September 2, 2025. During this session, Dr. Stamler will detail the Company's initiatives and advancements in the field of neurodegenerative treatments, specifically focusing on their flagship asset, ATH434.

Webcast Information

Individuals interested in attending the webcast can sign up for the Zoom session, where Dr. Stamler will share insights into the Company’s objectives and clinical trials. As Alterity continues to explore pathways for addressing the critical needs in the neurodegenerative space, this update represents an exciting opportunity for stakeholders to engage with the Company’s vision and strategic direction.

Company Overview

Alterity Therapeutics specializes in clinical-stage biotechnology, emphasizing the creation of effective therapies aimed at treating neurodegenerative diseases such as Parkinson's disease. The Company has registered meaningful efficacy for its lead product, ATH434, which underwent a randomized, double-blind, placebo-controlled Phase 2 clinical trial. This trial focused on participants suffering from Multiple System Atrophy (MSA), a rare and rapidly progressing form of Parkinson's disease, and has yielded promising results in its open-label Phase 2 trial.

Research and Development Strengths

One of the distinguishing features of Alterity is its robust drug discovery platform. This platform actively generates patentable chemical compounds specifically targeting the fundamental pathologies of neurological disorders. Through continuous innovation and scientific exploration, Alterity aims to reshape the future for individuals affected by these challenging diseases.

Investor Relations and Media Inquiries

Stakeholders seeking additional information about Alterity Therapeutics can reach out through the following contacts:

Contact Information in Australia

Ana Luiza Harrop
we-aualteritytherapeutics@we-worldwide.com
+61 452 510 255

Contact Information in the U.S.

Remy Bernarda
remy.bernarda@iradvisory.com
+1 (415) 203-6386

Frequently Asked Questions

1. What is the focus of Alterity Therapeutics?

Alterity Therapeutics focuses on developing innovative treatments for neurodegenerative diseases, with an emphasis on Parkinson's disease and related disorders.

2. Where will the Biotech Showcase take place?

The Biotech Showcase will take place simultaneously in Australia and the United States, allowing global participation.

3. Who is the CEO of Alterity Therapeutics?

The CEO of Alterity Therapeutics is David Stamler, M.D., who will lead the presentation at the Biotech Showcase.

4. What clinical trials are currently underway for ATH434?

ATH434 is undergoing clinical trials focused on Multiple System Atrophy, and the Company has reported promising outcomes from these trials.

5. How can I contact Alterity Therapeutics for more information?

For inquiries, you can contact Ana Luiza Harrop for Australian queries or Remy Bernarda for U.S. matters regarding investor relations.

About The Author

Dedicated Author and financial expert Logan Wright here, 29 years old. After earning an economics degree, I spent a number of years working in different financial industries. My great passion is enabling everyone, from any background or experience level, to understand and be literate in financial matters.

My books and writings are centered on simplifying difficult financial ideas into doable, understandable guidance. Whether it's retirement planning, investing, or budgeting, I want to arm readers with the information they need to make wise financial choices and realize their financial objectives.

Apart from writing, I also frequently post to financial blogs and organize webinars and workshops targeted at enlightening participants about personal finance. Always, my strategy is to offer concise, doable advice that can truly improve people's lives.

Away from work, I like to read, travel, and sample new foods. My goal is to infuse everything I do with the balance that I think is essential to both financial and personal well-being. By my profession, I want to encourage and enable people to confidently and clearly take charge of their financial futures.

Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.